Cointime reports: Zai Lab reported third-quarter total revenue of $108.2 million, with product revenue at $107.6 million, down 7% year over year but up 2% quarter over quarter. The sequential improvement came mainly from broader coverage and market penetration of core products and incremental sales from the launch of xanomeline trospium chloride, partly offset by lower tumor treating fields revenue.
Zai Lab Q3 revenue $108.2M, product sales down 7% YoY
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
18m ago
US semiconductor stocks plunge as data center investment outlook shifts
43m ago
S&P 500 Falls 2.0% to 7,498.13
44m ago
Nasdaq falls 3.3% as AI stocks sell off on Democratic midterm sweep
44m ago
US memory chip stocks extend selloff; SanDisk plunges over 17%
1h ago
Nvidia Falls 5.6%, Hitting Intraday Low Since April
1h ago
SanDisk, Western Digital, Seagate all fall over 11%; AMD drops 11%